Skip to main content
TipRanks
Go Ultimate75% OFF

Alvotech (Z45) AI Stock Analysis

0 Followers
DE:Z45

Alvotech

(Frankfurt:Z45)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving Commercial PerformanceThe sharp increase in product revenue and adjusted EBITDA indicates improving commercial traction as established products and newer launches gain reach. If sustained, stronger product-led performance can reduce reliance on licensing timing and support better operating leverage over coming quarters.
Negative Factors
High Leverage and Negative EquityThe combination of substantial debt and negative equity leaves Alvotech with limited financial flexibility. Leverage raises refinancing and interest burdens, constrains investment choices, and increases the consequences of operational delays or weaker product launches during the next several quarters.

Alvotech (Z45) vs. iShares MSCI Germany ETF (EWG)

-50%-40%-30%-20%-10%0%10%20%DE:Z45-11.41%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.56B
Dividend Yield
―
Average Volume (3M)
1,349
Price to Earnings (P/E)
-5.7
Beta (1Y)
0.58
Revenue Growth
-18.66%
EPS Growth
-399.21%
Country
Germany
Employees
1,279
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Alvotech Business Overview & Revenue Model

Company Description

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone dise...

Alvotech Earnings Call Summary

Earnings Call Date:Nov 11, 2026(Q3-2026)|% Change Since:-9.59%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with strong Q3 product revenue and EBITDA growth, improving manufacturing capacity and productivity, multiple regulatory milestones, expanding commercial reach, strong stated demand, and expectations for Q4 recovery and 2027 deleveraging. These positives were tempered by a 23% nine-month revenue decline, ongoing supply ramp-up, cash use and high interest payments, a full-year outlook trending toward the lower end of guidance, compressed 2026 product margins, and patent-related launch uncertainty.

Positive Updates

Strong Q3 Product Revenue Growth
Q3 product and service revenue increased to $58 million, up 78% year-on-year and 6% compared with Q2, reflecting a gradual recovery in commercial deliveries. Established products continued to show solid commercial traction while newer launches broadened the portfolio's geographic reach.

Negative Updates

Nine-Month Revenue Decline
First-nine-month total revenue was $323 million, down 23% year-on-year. Management attributed the decline to production timing, licensing revenue timing, and the impact of the U.S. Stelara biosimilar launch in the first half of the prior year.

Company Guidance

For the full year, Alvotech targets revenues in the range of $650 million to $700 million and Adjusted EBITDA in the range of $180 to $220 million, expects a significant proportion of full year revenue and EBITDA to be generated in the fourth quarter, expects the fourth quarter to be the strongest quarter of the year and the strongest in Alvotech history, and now expects performance to trend towards the lower end of our stated range; the company expects to deliver year on-year growth in 2026, cash flow positive in Q4 of 26, healthy deleveraging towards the later half of 2027, and substantial improvements on the upside between 26 in 2027, while 2027 guidance has not been provided, total R&D spend remains in the area of 200 million with 50% capitalized, product margins are expected to remain somewhat compressed through 2026 and have a stronger product margin profile as we enter into 2027, and interest payments are expected to remain around this level until deleveraging, which is somewhere in 2027.

Alvotech Risk Analysis

Alvotech disclosed 95 risk factors in its most recent earnings report. Alvotech reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We may need to refinance all or a portion of our indebtedness and cannot assure you that refinancing will be available on commercially reasonable terms, or at all.Q4, 2023
2.Termination or expiration of governmental programs or tax benefits, could adversely affect us.Q4, 2023
3.We operate our main R&D and manufacturing facility in Iceland which is an island with a relatively limited number of ports of entry by sea or air which may impact logistics. Geologic activity, in particular volcanic eruptions could impact transport and cause disruptions to our supply chain or ability to export product.Q4, 2023

Alvotech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:Z45 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TAKTAK67Neutral$68.79B28.185.07%3.32%0.67%-12.01%
VTRSVTRS67Neutral$23.25B-38.26-4.24%2.37%4.80%82.97%
RDYRDY66Neutral$12.38B41.617.37%0.56%-10.52%-55.45%
AMRXAMRX58Neutral$7.36B50.88131.71%―8.88%2272.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HCMHCM49Neutral$2.41B149.521.43%―-8.81%-96.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:Z45RDYVTRSHCMAMRXTAKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:Z45 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:Z45Alvotech3.96-0.52-11.61%
RDYDr. Reddy's Laboratories Ltd14.981.168.36%
VTRSViatris, Inc.20.2810.44106.08%
HCMHutchmed (China) Limited13.99-0.19-1.34%
AMRXAmneal Pharma21.8810.3690.01%
TAKTakeda Pharmaceutical Company21.277.2151.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.